ArticleScientific reports2017
PD-L1 expression in lung adenosquamous carcinomas compared with the more common variants of non-small cell lung cancer.
Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.
- Pooled it
- Integrated genomic and immunophenotypic profiling reveals monoclonal origin, smoking-driven evolution and heterogeneous microenvironment in pulmonary adenosquamous carcinoma.Frontiers in immunology · 2026Article
- A case of adenosquamous pancreatic cancer with a KRAS G12C mutation with an exceptional response to immunotherapy.Oncotarget · 2024Article
- Adenosquamous Carcinoma of the Lung: Survival, Radiologic Findings, PD-L1, and Driver Mutations.Journal of clinical medicine · 2024Article
- The Genetic Analysis and Clinical Therapy in Lung Cancer: Current Advances and Future Directions.Cancers · 2024Review
- PD-L1 expression in pancreaticobiliary adenosquamous carcinoma: a single-institution case series.Journal of gastrointestinal oncology · 2024Article
- Association of PD-L1 expression with driver gene mutations and clinicopathological characteristics in non-small cell lung cancer: A real-world study of 10 441 patients.Thoracic cancer · 2024Article
- Distant organ metastasis patterns and prognosis of lung adenosquamous carcinoma: a SEER database analysis.Interdisciplinary cardiovascular and thoracic surgery · 2024Article
- NPLOC4 is a potential target and a poor prognostic signature in lung squamous cell carcinoma.Scientific reports · 2023Article
- Targeted therapy for rare lung cancers: Status, challenges, and prospects.Molecular therapy : the journal of the American Society of Gene Therapy · 2023Review
- Ezrin regulates the progression of NSCLC by YAP and PD-L1.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2023Article
- Immune cellular patterns of distribution affect outcomes of patients with non-small cell lung cancer.Nature communications · 2023Article
- Clinical outcomes of immune checkpoint inhibitor therapy for advanced lung adenosquamous carcinoma.Journal of thoracic disease · 2023Article
- Article
- PD-L1 Over-Expression Varies in Different Subtypes of Lung Cancer: Will This Affect Future Therapies?Clinics and practice · 2022Review
- A review of spatial profiling technologies for characterizing the tumor microenvironment in immuno-oncology.Frontiers in immunology · 2022Review
- Heterogeneity of tumor immune microenvironment and real-world analysis of immunotherapy efficacy in lung adenosquamous carcinoma.Frontiers in immunology · 2022Article
- Distribution and Expression of Programmed Death Ligand -1 (PD-L1) in Non-Small Cell Carcinomas of the Lung in a Tertiary Care Centre in South India.Turk patoloji dergisi · 2021Article
- An Uncommon Lung Neoplasm in a Young Patient: Diagnostic Challenges.The American journal of case reports · 2020Article
- Transcriptional Spatial Profiling of Cancer Tissues in the Era of Immunotherapy: The Potential and Promise.Cancers · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung adenosquamous cell carcinomas (ASCs) is a rare variant of NSCLC with a poorer prognosis and fewer treatment option than the more common variants. PD-L1 expression is reported to be the predictor of clinical response in trials of NSCLC. In our study, PD-L1 expression was evaluated via immunohistochemistry using a specific monoclonal antibody (SP263), and PD-L1 mRNA expression was evaluated via in situ hybridization. This study included 51 ASCs, 133 lung adenocarcinomas, and 83 lung squamous cell carcinomas (SCC). Similar results were obtained for PD-L1 expression measured at the mRNA and protein level (k coefficient, 0.851, P = 1.000). PD-L1 expression was significantly higher in the squamous versus glandular component of the 36 ASCs in which the components were analyzed separately. The PD-L1 expression rate was similar in the squamous cell component of ASCs and lung SCC (38.89% vs. 28.92%, P = 0.293), so does the adenocarcinoma component of ASCs and lung adenocarcinomas (11.11% vs 13.53%, P = 1.000). PD-L1 expression correlated significantly with lymphovascular invasion (P = 0.016), but not with EGFR, KRAS, and ALK mutations in lung ASCs. Anit-PD-L1 is a promising treatment option in lung ASC cases in which PD-L1 upregulated and EGFR mutations are present.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.